Screener / SEC EDGAR /CIK 0001237831 /10-K filed Feb 24, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Medical Instruments

Globus Medical Inc GMED

Employees
6,000
Headquarters
Audubon, PA
Next results
around Jan 6, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $2.9B through the costs to a net profit of $537.9M · income statement of the 10-K

16% operating margin
Revenue to Gross profit: $2.0BRevenue to Cost of revenue: $957.8MGross profit to Operating profit: $479.8MGross profit to Operating expenses: $1.5BOperating profit to Net profit: $412.6MOperating profit to Tax: $67.2MOther income to Net profit: $125.3MOperating expenses to R&D: $147.2MOperating expenses to Sales, admin & other: $1.4B Revenue: $2.9B REVENUE $2.9B +17% Y/Y Gross profit: $2.0B · 67% margin GROSS PROFIT $2.0B 67% margin Cost of revenue: $957.8M · 33% of revenue COST OF REVENUE $957.8M 33% of revenue Operating profit: $479.8M · 16% margin OPERATING PROFIT $479.8M 16% margin · +189% Y/Y Other income: $125.3M · 4% of revenue OTHER INCOME $125.3M 4% of revenue Operating expenses: $1.5B · 51% of revenue OPERATING EXPENSES $1.5B 51% of revenue Net profit: $537.9M · 18% margin NET PROFIT $537.9M 18% margin · +422% Y/Y Tax: $67.2M · 2% of revenue TAX $67.2M 2% of revenue R&D: $147.2M · 5% of revenue R&D $147.2M 5% of revenue Sales, admin & other: $1.4B · 46% of revenue SALES, ADMIN & OTHER $1.4B 46% of revenue
Gross profit $2.0B 67% margin
Operating profit $479.8M 16% margin · +189% Y/Y
Net profit $537.9M 18% margin · +422% Y/Y
The full income statement, year by year

GMED among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 16.7%, above 69% of 154 peers (their median 10.4%) REVENUE GROWTH 16.7% · above 69% Gross margin: 69.1%, above 64% of 107 peers (their median 63.4%) GROSS MARGIN 69.1% · above 64% Operating margin: 21.6%, above 83% of 138 peers (their median 9.8%) OPERATING MARGIN 21.6% · above 83% Net margin: 17.8%, above 80% of 153 peers (their median 6.7%) NET MARGIN 17.8% · above 80% FCF margin: 24.4%, above 87% of 144 peers (their median 9.9%) FCF MARGIN 24.4% · above 87% Return on capital: 8.9%, above 47% of 89 peers (their median 9.2%) RETURN ON CAPITAL 8.9% · above 47%
GMED Peer median Below the median

What changed

9 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 24, 2026 against Feb 20, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Critical audit matters changed
    New this year: Business Combinations - Nevro Merger (“On April 3, 2025, the Company completed its merger with Nevro Corp. (“Nevro Merger”) with Nevro Corp. surviving as a wholly owned subsidiary of the Company, for total consideration of approximately $252.5 million. Management accounted for the acquisition as a business combination using the acquisiti”). Same as last year: Inventories Valuation
  • Receivables +21.7% ($557.7M to $678.9M) vs revenue +16.7% ($2.5B to $2.9B), +5.1 pts apart
9 more checks with nothing to note
  • Cash from operations $753.4M vs net income $537.9M (FY ending Dec 31, 2025)
  • Inventory +15.2% ($659.2M to $759.3M) vs revenue +16.7% ($2.5B to $2.9B), -1.5 pts apart
  • Same auditor in both 10-Ks: DELOITTE & TOUCHE LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

9 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.

All 9 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    Additionally, during 2025, Daniel Scavilla, our former Chief Executive Officer, resigned from the Company and was replaced by Mr. Pfeil, who had previously served as the Chief Operating Officer and Chief Financial Officer. Although the Board is confident in the leadership of Mr. Pfeil, leadership transitions can be inherently difficult…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    In 2025, the U.S. enacted the imposition of widespread and substantial tariffs on imports, which resulted in the imposition of reciprocal or retaliatory tariffs and continued tariff volatility and uncertainty. The tariffs enacted by the U.S. included a universal baseline tariff of 10%, plus an additional country-specific tariff for…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    The Company’s Bylaws provide, to the fullest extent permitted by law, that the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal actions between the Company and its stockholders, which could increase costs to bring a claim, discourage claims or limit the ability of the Company’s stockholders to…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.0B$1.6B$2.5B$2.9B
Net income$190.2M$122.9M$103.0M$537.9M
Operating cash flow$178.5M$243.5M$520.6M$753.4M
Free cash flow$104.4M$165.2M$405.2M$588.8M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.9B ▲ 16.7% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

5 filings in the last 30 days · SEC EDGAR

All filings

About the company

Globus Medical Inc, Audubon, PA · from the 10-K filed Feb 24, 2026

Globus Medical, Inc. (together, as applicable, with its consolidated subsidiaries, “Globus,” the “Company,” “we,” “us” or “our”), headquartered in Audubon, Pennsylvania, is a medical device company that develops and commercializes healthcare solutions whose mission is to improve the quality of life of patients with musculoskeletal disorders. Founded in 2003, Globus is committed to medical device innovation and delivering exceptional service to hospitals, ambulatory surgery centers and physicians to advance patient care and improve efficiency.

Headquarters
Audubon, PA
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had over 6,000 employees worldwide, including sales and marketing, product development, operations, general administrative and accounting, both domestically and internationally" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GMED/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.